Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 8/2019

01-08-2019 | Ciprofloxacin | Letter to the Editor

Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: a case report

Authors: Masaya Taniwaki, Shinya Katsutani, Masahiro Yamasaki, Kazuma Kawamoto, Kunihiko Funaishi, Yu Matsumoto, Naoko Matsumoto, Nobuyuki Ohashi, Noboru Hattori

Published in: Annals of Hematology | Issue 8/2019

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Ang AL, Kuperan P, Ng CH, Ng HJ (2009) Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101:852–859CrossRefPubMed
2.
Kane WH, Davie EW (1988) Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 71:539–555PubMed
3.
Bayani N, Rugina M, Haddad-Vergnes L, Lelong F (2002) High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors. Am J Hematol 71:33–36CrossRefPubMed
4.
Miesbach W, Voigt J, Peetz D, Scharrer I (2003) Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin. Med Klin (Munich) 98:339–343CrossRef
Metadata
Title
Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: a case report
Authors
Masaya Taniwaki
Shinya Katsutani
Masahiro Yamasaki
Kazuma Kawamoto
Kunihiko Funaishi
Yu Matsumoto
Naoko Matsumoto
Nobuyuki Ohashi
Noboru Hattori
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 8/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-019-03638-6

Other articles of this Issue 8/2019

Annals of Hematology 8/2019 Go to the issue

Letter to the Editor

Successful management of transcatheter aortic valve implantation by platelet transfusions in a nonagenarian patient with severe autoimmune factor V deficiency

Letter to the Editor

Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma

Letter to the Editor

Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia

Original Article

The abnormal function of CD39+ regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopenia

Letter to the Editor

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma

Original Article

Colla corii asini might upregulate ZNF471 and THOC5 by KRAB domain–containing zinc-finger protein pathway and THO complex subunit 5 pathway to improve anemia of pregnant women with β-thalassemia

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits